Treatment of unresectable glioblastoma multiforme

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4605-4610

  Nieder, Carsten ^a   Grosu, Anca L ^a   Astner, Sabrina ^a   Molls, Michael ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chemotherapy; Glioblastoma multiforme; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOGEN; CARMUSTINE; CISPLATIN; ETOPOSIDE; FOTEMUSTINE; NICOTINAMIDE; NIMUSTINE; NITROSOUREA; TEMOZOLOMIDE;

ARTICLE; CLINICAL TRIAL; DECISION MAKING; GLIOBLASTOMA; HUMAN; INOPERABLE CANCER; METHYLATION; MOLECULAR MODEL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; DACARBAZINE; GLIOBLASTOMA; HUMANS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS;

EID: 28444481643     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Nieder C, Grosu AL, Metha MP et al: Treatment of malignant gliomas in adults: radiotherapy, chemotherapy and integration of new targeted agents. Expert Rev Neurother 4: 691-703, 2004.
2. Walker MD, Strike TS and Sheline GE: An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5: 1725-1731, 1979.
3. Simpson JR, Horton J, Scott CB et al: Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive RTOG clinical trials. Int J Radiat Oncol Biol Phys 26: 239-244, 1993.
4. Keles GE, Anderson B and Berger MS: The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52: 371-379, 1999.
5. Laws ER, Parney IF, Huang W et al: Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99: 467-473, 2003.
6. Medical Research Council Brain Tumour Working Party: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 19: 509-518, 2001.
7. Kocher M, Kunze S, Eich HT et al: Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. Strahlenther Onkol 181: 157-163, 2005.
8. Jeremic B, Shibamoto Y, Grujicic D et al: Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study. J Neurooncol 51: 133-141, 2001.
9. Simon JM, Noel G, Chiras J et al: Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme. Radiother Oncol 67: 45-51, 2003.
10. Stupp R, Dietrich PY, Ostermann Kraljevic S et al: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 1375-1382, 2002.
11. Stupp R, Mason WP, van den Bent MJ et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
12. Combs SE, Gutwein S, Schulz-Ertner D et al: Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Strahlenther Onkol 181: 372-377, 2005.
13. Balana C, Lopez-Pousa A, Berrocal A et al: Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. J Neurooncol 70: 359-369, 2004.
14. Barrie M, Couprie C, Dufour H et al: Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann Oncol, epub April 27, 2005.
15. Frenay M, Lebrun C, Lonjon M et al: Up-front chemotherapy with fotemustine(F)/cisplatin(CDDP)/etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas. Eur J Cancer 36: 1026-1031, 2000.
16. Prestwich RJ, Sivapalasunrtharam A, Johnston C et al: Survival in high-grade glioma: a study of survival in patients unfit for or declining radiotherapy. Clin Oncol (R Coll Radiol) 17: 133-137, 2005.
17. Marshall LF and Langfitt W: Needle biopsy, high-dose corticosteroids, and radiotherapy in the treatment of malignant glial tumors. Natl Cancer Inst Monogr 46: 157-160, 1977.
18. Coffey RJ, Lunsford LD and Taylor FH: Survival after stereotactic biopsy of malignant gliomas. Neurosurgery 22: 465-473, 1988.
19. Nieder C, Nestle U, Ketter R et al: Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme. Radiat Oncol Invest 7: 36-41, 1999.
20. Curran WJ, Scott CB, Horton J et al: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85: 704-710, 1993.
21. McDonald DR, Cascino TL, Schold SC et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990.
22. Schiff D and Shaffrey ME: Role of resection for newly diagnosed malignant gliomas. Expert Rev Anticancer Ther 3: 621-630, 2003.
23. Vuorinen V, Hinkka S, Parkkila M et al: Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien) 745: 5-10, 2003.
24. Fine HA, Dear KB, Loeffler JS et al: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597, 1993.
25. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018, 2002.
26. Athanassiou H, Synodinou M, Maragoudakis E et al: Randomized phase II study of temozolomide and radiotherapy with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23: 2372-2377, 2005.
27. Roa W, Brasher PMA, Bauman G et al: Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22: 1583-1588, 2004.
28. Brada M, Ashley S, Dowe A et al: Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Ann Oncol 16: 942-949, 2005.
29. Lammering G, Hewit TH, Valerie K et al: Anti-erbB receptor strategy as a gene therapeutic intervention to improve radiotherapy in malignant human tumours. Int J Radiat Biol 79: 561-568, 2003.
30. Emrich JG, Brady LW, Quang TS et al: Radioiodinated (1-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am J Clin Oncol 25: 541-546, 2002.
31. Reardon DA, Akabani G, Coleman RE et al: Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20: 1389-1397, 2002.
32. Hegi ME, Diserens AC, Gorlia T et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
33. Nutt CL, Mani DR, Betensky RA et al: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63: 1602-1607, 2003.
34. Shai R, Shi T, Kremen TJ et al: Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22: 4918-4923, 2003.